Latest news

• Oncology directions

  For advanced breast cancer, Novartis's newly acquired breast cancer drug Tyverb (lapatinib) scores five, but there are four drugs that score three or less, including Eisai's breast cancer medicine

• Novartis and GSK complete oncology and vaccines swap

  Details of the asset swap were first revealed last April. Novartis claims ownership of several marketed products - including kidney cancer therapy Votrient (pazopanib) and Tyverb (lapatinib) for breast cancer - and also

• England's Cancer Drugs Fund: Fixing a broken system

  eribulin), GSK's Tyverb (lapatinib) and Novartis' Afinitor (everolimus)), were to be de-listed. ... GlaxoSmithKline's Tyverb (lapatinib):. treatment of advanced breast cancer. GlaxoSmithKline's Arzerra (ofatumumab):.

• Pharma condemns Cancer Drugs Fund cuts

  GSK. Arzerra (ofatumumab). Chronic lymphocytic leukaemia. Tyverb (lapatinib). Breast cancer. Votrient (pazopanib).

• NHS names drugs to be re-evaluated for Cancer Drugs Fund

  Chronic lymphocytic leukaemia. GlaxoSmithKline. Arzerra (ofatumumab)  . Chronic lymphocytic leukaemia. Tyverb (lapatinib).